BioChain Threatens Legal Action Against Epigenomics for Contract Termination
Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.
Epigenomics, BioChain Ink Lung Cancer Dx Deal in China
The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.
UPDATE: BioChain to Supply FFPE Samples to ArcherDx
The samples, which include non-small cell lung cancer samples, will be screened for cancer fusions, copy number variations, SNPs, and insertions and deletions.
Epigenomics' Epi proColon Test Included in China's Colorectal Cancer Screening Guideline
The Chinese guideline recommends the use of the Septin-9 DNA methylation assay as the standard of care for early colorectal cancer screening.